Market Pulse: Markets edge sideways as investors digest SpaceX’s massive bond strategy and burgeoning biotech claims.
Key Movers: SpaceX’s rumored $20 B debt push (Crypto Briefing) and uniQure’s accelerated FDA path for AMT-130 (Medical Daily) share headlines with Insight Molecular Diagnostics’ rapid tumor test (Yahoo Entertainment) grabbing attention.
Macro & Politics: L.A. AGs challenge on ParaBros merger signals antitrust heat and China’s state-led brain chip rollout (Fox News) underscores strategic data risks.
What’s Next: Keep tabs on the House debate over likeness-rights and the FDA mRNA flu vaccine panel expected to convene early today.
What everyone’s missing is how a bond-laden SpaceX balance sheet soaked in Bitcoin could turn toxic if rates spike or crypto tanks. Crypto Briefing’s “SpaceX plans $20B bond deal following record $75B IPO, reveals 18,712 Bitcoin on balance sheet” flags 18,712 Bitcoin, yet few are talking about the margin calls that could follow a sudden selloff. Locking in cheap debt only looks smart until the market shakes off complacency.
Here’s a thesis: the same government urgency that greases uniQure’s AMT-130 accelerated FDA path (Medical Daily) is fueling China’s NEO brain chip rollout (Fox News), blending health innovation with political power plays. Don’t overlook how state-backed tech can shift the competitive landscape overnight, especially when regulators hold veto rights.
Action time: positions in IMDX (Yahoo Entertainment) and ParaBros merger targets (Deadline) are flirting with deep downside if clinical data or antitrust suits hit. Dial in your stops, survey the legal timetables, and remember that headlines don’t wait for your portfolio to catch up.
uniQure announced June 17, 2026: FDA agreed that 3-year AMT-130 Phase I/II data supports an accelerated approval BLA for Huntington's disease. BLA submission planned Q3 2026.
Midjourney is moving beyond AI image generation with a planned full-body ultrasonic scanner that promises MRI-like 3D imaging in under 60 seconds. Developed with Butterfly Network, the project aims to debut in a San Francisco spa before seeking FDA approval.
I keep hitting the buy button on Apple (NASDAQ:AAPL), and the June panic over Fed Chair Kevin Warsh has only made my finger faster. Momentum traders are dumping amid chatter of rising rates.
FDA approved generic baloxavir June 17; VRBPAC voted on mRNA flu vaccine June 18. The 2025–26 flu season killed 24,000 Americans. Here's what both mean for 2026–27.
Eli Lilly (NYSE:LLY) just reported a quarter that should have sent bulls into a frenzy. Revenue grew 55.5% year over year to $19.80 billion, driven by Mounjaro.
Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is one of the high-growth micro-cap stocks to buy now. On June 11, Insight Molecular Diagnostics Inc. released data on its point-of-care tumor analysis platform, sparking debate.
With worrying numbers about potential L.A. job losses and other economic impacts resulting from a Paramount-Warner Bro merger, the Los Angeles County Board of Supervisors has just put its thumb on the scale of a possible state attorneys general’s challenge.
China approves NEO brain chip for commercial medical use in paralysis patients, raising questions about neural data privacy and cybersecurity risks.
This week in Other Barks & Bites: Circuit Judge Leonard Stark authors a concurrence explaining the Federal Circuit’s changes to the skilled searcher test in Ironburg Inventions v. Valve; Senate committees separately advance bills aimed at clarifying the framework.
The US-Iran peace deal has brightened the outlook for European stocks in the second half and prompted several strategists to increase their year-end targets, according to a Bloomberg survey.
For the first time ever, you have the rare chance to profit BEFORE the upcoming IPO. Click here now for the urgent details on this hidden play.
Somewhere in the past few weeks, a supply chain rumor got out that a chip program Broadcom has been working on with Google might be running late. Nobody conf…
SpaceX's financial strategy intertwines high-stakes AI expansion with volatile crypto holdings, posing significant risk to bond investors.
Midjourney is expanding beyond AI image generation with plans for a medical-imaging business built around a water-based, full-body ultrasound scanner that uses AI to reconstruct MRI-like images.
The Centrus-Oklo deal highlights the growing importance of domestic HALEU production, potentially reshaping the U.S. nuclear energy landscape.
Vancouver, British Columbia — Life Sciences BC is pleased to announce the recipients of the 28th Annual Awards, recognizing outstanding individuals and organizations advancing health innovation across British Columbia.
Have you heard the big news? Elon Musk's company Starlink is preparing to announce their IPO as soon as March 26th! Click here now for the time-sensitive details.